ArticleScience progress
Association between admission Braden skin score and poor prognosis in critically ill patients with diabetes mellitus: A retrospective cohort study.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectivesDiabetes mellitus (DM) is a common comorbidity in intensive care unit (ICU) patients. The Braden skin score (BSS) has increasingly been recognized as an indicator of patient frailty. However, the association between the BSS and clinical outcomes in critically ill diabetic patients remains unclear. This study aimed to investigate the relationship between the BSS and clinical outcomes in diabetic patients in ICU settings.MethodsA retrospective cohort of diabetic patients with measured BSS was identified from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. The primary outcomes included mortality at 30, 60, and 90 days. The association between BSS and survival outcomes was evaluated using time-dependent Cox proportional hazards model. Further validation was conducted through Kaplan-Meier survival analysis, restricted cubic spline fitting, and subgroup analyses.ResultsA total of 20,590 patients were included in this study, those with higher BSS had a 14% decreased risk of 30-day mortality (HR: 0.86, 95% CI: 0.84-0.87,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.